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We have examined the role of integrin–extracellular matrix interactions in the morphogenesis of ductal structures in vivo
using the developing mouse mammary gland as a model. At puberty, ductal growth from terminal end buds results in an
arborescent network that eventually fills the gland, whereupon the buds shrink in size and become mitotically inactive. End
buds are surrounded by a basement membrane, which we show contains laminin-1 and collagen IV. To address the role of
cell–matrix interactions in gland development, pellets containing function-perturbing anti-b1 integrin, anti-a6 integrin, and
nti-laminin antibodies respectively were implanted into mammary glands at puberty. Blocking b1 integrins dramatically
reduced both the number of end buds per gland and the extent of the mammary ductal network, compared with controls.
These effects were specific to the end buds since the rest of the gland architecture remained intact. Reduced development
was still apparent after 6 days, but end buds subsequently reappeared, indicating that the inhibition of b1 integrins was
reversible. Similar results were obtained with anti-laminin antibodies. In contrast, no effect on morphogenesis in vivo was
seen with anti-a6 integrin antibody, suggesting that a6 is not the important partner for b1 in this system. The studies with
b1 integrin were confirmed in a culture model of ductal morphogenesis, where we show that hepatocyte growth factor
(HGF)–induced tubulogenesis is dependent on functional b1 integrins. Thus integrins and HGF cooperate to regulate ductal
orphogenesis. We propose that both laminin and b1 integrins are required to permit cellular traction through the stromal
matrix and are therefore essential for maintaining end bud structure and function in normal pubertal mammary gland
development. © 1999 Academic PressKey Words: integrin; mouse mammary gland; morphogenesis; hepatocyte growth factor; extracellular matrix; laminin.
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fINTRODUCTION
Tissue morphogenesis relies on the dynamic interactions
of cells with each other and with the extracellular matrix
(ECM).2 Key molecules involved in these interactions are
the integrin family of cell surface ECM receptors. Most
integrin functions have been defined using culture models
and blocking antibodies, disintegrins, antisense constructs,
1 To whom correspondence should be addressed. Fax: 144 161
275 3915. E-mail: tklinows@fs1.scg.man.ac.uk.
2 Abbreviations used: ECM, extracellular matrix; EHS, En-
elbreth–Holm–Swarm; H&E, haematoxylin and eosin; HGF, he-
atocyte growth factor; TGF, transforming growth factor; SDS,e
H
odium dodecyl sulphate; PAGE, polyacrylamide gel electrophore-
is.
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All rights of reproduction in any form reserved.r peptides corresponding to binding sites (Adler and Chen,
992; Lallier et al., 1992; Trikha et al., 1994). Such inter-
erence with cell–ECM communication has been demon-
trated to affect cell adhesion, migration, differentiation
tate, gene expression, proliferation, and survival (reviewed
n Ashkenas et al., 1996). However, it is still largely
nresolved as to whether integrins are involved in similar
echanisms in vivo.
A number of studies have explored the effect of injecting
ntegrin-blocking antibodies intravenously. These have
oncentrated on the subsequent behaviour of cells of the
mmune system (Abraham et al., 1994; Gorcyznski et al.,
995; Weg et al., 1993) or the degree of metastatic spread
rom primary tumours (Elliott et al., 1994), which are
ssentially effects on single cells or small groups of cells.
owever, most cells in vivo do not exist singly but rather as
13
n
b
m
s
F
i
m
t
i
n
a
v
a
r
e
a
s
t
c
a
m
i
T
c
i
t
w
l
s
a
o
s
a
b
p
14 Klinowska et al.a three-dimensional multicellular architecture, and few
studies have explored how integrin function relates to the
development and maintenance of tissue structure.
To investigate the importance of integrins in tissue
morphogenesis, their role in developing systems in vivo
eeds to be examined and to this end, knockout mice have
een created by homologous recombination. However,
any homozygous integrin deletions are lethal at early
tages of development (reviewed by Hynes, 1996, and
assler et al., 1996). Thus in order to study the function of
ntegrins in late-developing organ systems such as the
ammary gland, other approaches are required. The injec-
ion of function-blocking antibodies into specific sites of
nterest has been used in several developmental models. In
onmammalian systems, the presence of anti-b1 integrin
ntibody blocks interstitial cell migration of Hydra grafts in
ivo (Agbas and Sarras, 1994), while injection of anti-b1
ntibodies into the blastocoel of amphibian embryos dis-
upts gastrulation and mesodermal cell migration (Boucaut
t al., 1984; Howard et al., 1992; Johnson et al., 1993). In
vian embryos, introduction of antibodies to b1 integrins
into cranial neural crest cell migratory pathways results in
serious perturbation of normal migration (Bronner Fraser,
1985). However, this approach has not previously been used
to investigate integrin function in developing mammalian
tissues in vivo.
In this study we have used the mammary gland as a
model system to examine the role of integrin–matrix inter-
actions in ductal morphogenesis. At birth the murine
mammary gland is a simple rudiment consisting of a few
ducts that extend from the nipple a short distance into the
subcutaneous fat pad. Glandular growth then arrests until
the onset of puberty at around 3 weeks of age when cells in
bulbous structures at the ductal tips, known as end buds,
begin to proliferate, resulting in lengthening and branching
of the epithelial ductal network. This growth results in an
arborescent network of interconnecting tubes, which even-
tually fills the subcutaneous fatty stroma of the gland. In
areas where there is no room for further ductal expansion,
the end buds regress to become quiescent terminal struc-
tures. By contrast, active terminal end buds are highly
mitotic, multilayered epithelial structures found only dur-
ing ductal growth. They consist of a teardrop-shaped group
of cells containing 6–10 layers of body or luminal cells.
This is surrounded by an outer layer of cap cells at the tip of
the end bud and myoepithelial cells at its neck and extend-
ing along the length of the duct. These lie on a specialised
form of ECM, the basement membrane. The duct in turn is
ensheathed in a collagenous stroma that extends along its
length up to the neck of the end bud. The fibrous stroma
may constrict the direction of growth by only allowing
ductal elongation from the tip of the end bud (Williams and
Daniel, 1983); side branches form in areas of breaks in the
sheath. The mammary ductal network is in turn sur-
rounded by the adipose cells of the fat pad.A number of factors have been shown to affect end bud
formation and ductal elongation including growth factors
Copyright © 1999 by Academic Press. All rightuch as transforming growth factor (TGF) a and b, epider-
mal growth factor, and hepatocyte growth factor (HGF),
hormones such as oestrogen and growth hormone, and cell
adhesion molecules including E- and P-cadherin (Coleman
et al., 1988; Daniel et al., 1995; Kleinberg, 1997; Silberstein
and Daniel, 1987; Snedeker et al., 1991; Yang et al., 1995).
We now present a study examining the role of integrin–
matrix interactions in the developing virgin mammary
gland in vivo. Earlier work using culture models of primary
mammary epithelial cells isolated from pregnant mice has
demonstrated a role for integrin–ECM interactions in the
suppression of apoptosis and also in milk production at a
later stage of mammary gland development (Pullan et al.,
1996; Streuli et al., 1991), and b1 integrin has been shown
to be required for full pregnancy–associated development in
vivo (Faraldo et al., 1998). However, it has not previously
been determined whether integrin receptors have an addi-
tional role in the control of ductal elongation during devel-
opment in the nonpregnant pubertal virgin animal.
To address this question, we examined the effect of
function-blocking anti-b1 and anti-a6 integrin antibodies
on ductal morphogenesis and report here for the first time
that blocking b1 but not a6 integrin dramatically reduces
he number of end buds in the gland in vivo compared with
ontrols. Furthermore, we show that the anti-b1 integrin
ntibody disrupts morphogenesis in a culture model of
ammary tubulogenesis. Similar results were also obtained
n vivo with a function-blocking anti-laminin antibody.
hese effects were not due to simple disruption of all
ell–matrix interactions since the mammary gland retained
ts histoarchitecture; the effects observed were specific to
he developing buds. We therefore propose that contact
ith the extracellular matrix, and with laminin in particu-
ar, via b1 integrins is a key factor in maintaining end bud
tructure and function, and thus that normal development
nd ductal morphogenesis of the mammary gland depend
n functional b1 integrins. We also demonstrate that the
key partner for these interactions is not the a6 integrin
ubunit.
MATERIALS AND METHODS
Antibody Preparation
The detailed method for the preparation of the anti-b1 integrin
ntibody is published elsewhere (Edwards and Streuli, 1999). In
rief, rat monoclonal antibody PS/2 (anti-a4 integrin) was used to
urify a4b1 integrin from E14.5–16.5 mouse embryo homogenate.
After prebleeding, two New Zealand White rabbits were immu-
nized with 50 mg purified a4b1 integrin and boosted after 12 weeks.
Rabbit IgG was purified by protein A chromatography, but not
further purified on an integrin column because we wished to retain
as much of the integrin function-perturbing component of the
antiserum as possible. An antibody to the COOH-terminal domain
of the mouse b1 integrin subunit was developed in rabbits and
affinity-purified on an integrin peptide column as described previ-
ously (Delcommenne and Streuli, 1995). Rabbit polyclonal antibod-
ies against purified Engelbreth–Holm–Swarm (EHS) tumour
s of reproduction in any form reserved.
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15b1 Integrins and Mammary Morphogenesislaminin-1 and mouse laminin E3 fragment specific for the laminin
a1 chain (kind gifts of P. Yurchenko) were also raised in this
laboratory. Purified IgG fractions were subsequently affinity-
purified on EHS–Sepharose columns. Rat anti-a6 integrin mono-
lonal antibody (GoH3) was obtained from Serotec (Oxford, UK), as
as the appropriate rat IgG2a control antibody.
Pellet Preparation
Elvax pellets were prepared according to the methods of Silber-
stein and Daniel (1982). Briefly, 10 mg of anti-b1 integrin, anti-
aminin, anti-E3, or control rabbit IgG or 1 mg of anti-a6 integrin or
control rat IgG2a was added to 20 mg bovine serum albumin
(Sigma) and lyophilised. The lyophilate was mixed with 250 ml of a
10% (w/v) Elvax (Dupont, gift of G. Silberstein) solution in dichlo-
romethane and immediately frozen. The resulting pellet was left to
dry overnight at 220°C and then vacuum desiccated. Antibody
content was calculated as weight of incorporated material (i.e., 10
or 1 mg antibody respectively) per total weight of pellet. The large
original pellet was cut into smaller pieces (;1 mm3) for implanta-
tion. The typical amount of antibody implanted in these experi-
ments was 300 mg/pellet piece for rabbit polyclonal or 30 mg/pellet
iece for rat monoclonal antibodies.
Implantation of Pellets
Age-matched 5-week-old virgin ICR or MF1 outbred mice were
anaesthetised and the ventral skin was retracted to expose both
abdominal No. 4 mammary glands. A small pocket was made in the
fat pad of one gland proximal to the lymph node (i.e., just in front
of the advancing ducts), and an antibody pellet was inserted. The
contralateral gland 4 either had no implant or had a control IgG
pellet. The skin was then sutured closed. The mice were adminis-
tered analgesia and left to recover on a heated pad.
BrdU Injection and Detection
To assess proliferation rates in the mammary gland, 10 ml BrdU
abelling reagent (Amersham International Plc, Little Chalfont,
K) per gram of mouse body weight was injected intraperitoneally
h before the glands were removed from the mouse and processed
or whole-mounting, cryoembedding, or paraffin embedding. De-
ection of BrdU incorporation in paraffin sectioned tissue was
erformed using an anti-BrdU primary antibody and an alkaline
hosphatase-conjugated secondary antibody to cause a colour reac-
ion with DAB-Ni (Amersham). Sections were counterstained with
.5% methyl green in 0.1 M sodium acetate, pH 4.0, for 15 min.
roliferation indices were calculated as the proportion of labelled
ells in an end bud.
Mammary Gland Whole-Mount
Mice were killed by cervical dislocation. The No. 4 glands were
removed and spread flat on microscope slides, fixed in 70%
ethanol, 5% formalin, 5% glacial acetic acid, and defatted in
acetone. Cell nuclei were stained with haematoxylin. The tissue
was then dehydrated sequentially in ethanol and cleared in 100%
methyl salicylate. Photomicrographs were taken on Kodak Ekta-
chrome 160T film using an Olympus OM4 camera mounted on a
Leica dissecting microscope.
Copyright © 1999 by Academic Press. All rightParaffin Embedding
Number 4 glands were removed, cut into pieces, fixed in 4%
paraformaldehyde (1 h at 4°C), and embedded in paraffin using
standard techniques. Alternatively, for tissue that had already been
whole-mounted, pieces of gland were cut from slides and washed in
two changes of xylene before being embedded in wax. Five-
micrometer sections were cut on a rotary microtome and mounted
on uncoated glass slides.
Haematoxylin and Eosin Staining (H&E Staining)
Paraffin sections were dewaxed in xylene and rehydrated
through alcohols. After a wash in distilled water, slides were
stained for 1 min in Harris’s haematoxylin, “blued” in tap water,
and stained for 1 min in eosin. Tissue that had been whole-
mounted and stored in methyl salicylate before sectioning required
longer staining in eosin and less time in haematoxylin.
Assessment of Apoptotic Indices
Apoptosis was quantified by examining H&E-stained paraffin
sections under an Olympus microscope. Apoptotic cells were
defined as those that had dark, condensed, and lobular nuclei and
whose cytoplasm was eosinophilic. In our experience this is a
much more reliable and reproducible indicator of apoptosis than
TUNEL labelling for this tissue. End buds were identified and the
number of apoptotic cells as a proportion of the total number of
cells in each end bud section was calculated.
Cryoembedding
Number 4 glands were removed, placed in OCT mounting
medium (Tissue-tek), and frozen. Sections (7 or 30 mm) were placed
n glass slides, fixed in precooled methanol:acetone 1:1 at 220°C
10 min), and stored at 220°C until required.
Immunocytochemistry
Immunocytochemistry was performed as previously described
(Streuli and Bissell, 1990). Anti-b1 integrin antibody was used at 10
mg/ml. Anti-laminin-1 and laminin E3 fragment antibodies were
used at 1 and 3 mg/ml, respectively. Rabbit polyclonal serum raised
n this laboratory against collagen IV was used at 1:100 dilution.
onkey anti-rabbit FITC-conjugated secondary antibody was used
t a concentration of 1:100 (Jackson ImmunoResearch Laborato-
ies, Inc.). Nuclei were counterstained with 4 mg/ml Hoechst 33258
and mounted in 1 mg/ml p-phenylene diamine in 10% PBS, 90%
glycerol, pH 8.0. Stained sections were examined on a Zeiss
epifluorescence microscope and photographed using Tmax 400
film or on a Leica confocal microscope.
Metabolic Labelling and Immunoprecipitation
of Integrins
This was performed as previously described (Delcommenne and
Streuli, 1995). Briefly, K-1735 M2 melanoma, CID-9, or primary
mammary epithelial cells were radiolabelled overnight with
[35S]methionine (NEN) and lysed in 50 mM Tris, pH 8.0, 150 mM
NaCl, 1% Nonidet-P40, 1 mM CaCl2, 1 mM MgCl2 containing 0.45
TIU/ml aprotinin, 10 mM leupeptin, 0.5 mM PMSF, and 1.5 mM
s of reproduction in any form reserved.
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16 Klinowska et al.pepstatin A (Sigma). Aliquots of lysates containing equal TCA-
precipitable counts were reacted with 10 mg antibody and immune
complexes precipitated with protein A–Sepharose (Zymed Labora-
tories Inc., South San Francisco, CA). The bound complexes were
washed and analysed by SDS–PAGE under nonreducing conditions
on 6.25% gels. Gels were dried and autoradiographed with Kodak
XAR-5 film at 270°C.
Immunoblotting
Purified laminin-1 (0.2 mg) or its E3 component, EHS matrix, and
purified collagen IV (Becton Dickinson Oxford, UK) were separated
under reducing conditions on 4.0–7.5% SDS–polyacrylamide gra-
dient gels, transferred to Immobilon-P membrane (Millipore LTD.,
Oxford, UK), incubated with 1 mg/ml affinity-purified anti-laminin
r anti-E3 polyclonal antibodies and detected by enhanced chemi-
uminescence using an ECL kit (Amersham).
Adhesion Assays
First-passage primary mouse mammary epithelial cells, CID-9 or
FSK-7 mammary epithelial cell lines (Pullan and Streuli, 1996; 4 3
104 cells/well), were incubated for 60 min in the presence of 0–400
mg/ml anti-b1 integrin, anti-laminin-1, or anti-E3 IgG or 400 mg/ml
control rabbit IgG in 96-well dishes (Maxisorb, Nunc, Kampstrup
Roskilde, Denmark) coated with physiological substrata (12 mg/ml
fibronectin, 2 mg/ml collagen IV, 12 mg/ml laminin-1, and 3 mg/ml
vitronectin (all Sigma), or 16 mg/ml collagen I and 1 mg/ml EHS
matrix; Pullan and Streuli, 1996). After unattached cells were
washed away, adhered cells were fixed, stained with crystal violet,
and solubilised in 2 M guanidine hydrochloride before the absor-
bance was read at 595 nm.
Culture Assay for Mammary Ductal
Morphogenesis
TAC-2.1 cells (Soriano et al., 1996), a clonally derived subpopu-
ation of the TAC-2 cell line (Soriano et al., 1995), were cultured in
issue culture flasks (Falcon, Becton Dickinson and Co., San Jose´,
A) coated with collagen I in DME (Gibco, Basel, Switzerland)
upplemented with 10% FCS (Gibco), penicillin (110 iu/ml), and
treptomycin (110 mg/ml). Recombinant human HGF was a gener-
us gift of Dr. R. Schwall (Genentech Inc., South San Francisco,
A). TAC-2.1 cells were suspended at 6 3 103 cells/ml in collagen
els (500 ml) in 16-mm wells of four-well plates (Nunc) and
incubated in 500 ml medium with or without HGF and anti-b1
integrin antibody. Medium and treatments were renewed every 2–3
days. After 9 days, the cultures were fixed with 2.5% glutaralde-
hyde in 0.1 M cacodylate buffer, and at least three randomly
selected fields (measuring 2.2 mm 3 3.4 mm) per experimental
condition in each of at least three separate experiments were
photographed under bright-field illumination with a Nikon Dia-
phot TMD inverted photomicroscope. The total length of cords in
each individual colony was measured with a Qmet 500 image
analyser (Leyca Cambridge Ltd., Cambridge, UK). Cord length was
considered as 0 in (a) spherical colonies and (b) slightly elongated
structures in which the length to diameter ratio was less than 2.
Values for cord length obtained from the largest colonies are an
underestimate, since in these colonies a considerable proportion of
the cords were out of focus and therefore could not be measured.
Values are expressed as mean cord length per photographic field
(Soriano et al., 1996). The mean values for each experimental
Copyright © 1999 by Academic Press. All rightcondition were compared to controls using Student’s unpaired T
test.
Analysis of c-Met Phosphorylation
TAC-2.1 cells were cultured on collagen I to subconfluency,
serum starved overnight, and treated with 20 mg/ml HGF (R&D
ystems, Abingdon, UK) and/or 50 mg/ml anti-b1 integrin antibody
or control IgG. Cells were washed in ice-cold PBS containing 1 mM
Na3VO4, 1 mM NaF (Sigma) and their contents were extracted with
lysis buffer (1% Triton X-100, 1 mM PMSF, 50 mM Tris, pH 7.5,
150 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 10 mM
eupeptin and aprotinin). After the detergent insoluble proteins
ere cleared by centrifugation, equal amounts of protein (as
stimated by Coomassie-stained gel electophoresis) were immuno-
recipitated with anti-c-Met antibody (Santa Cruz Biotechnology
nc., Santa Cruz, CA) or control rabbit IgG followed by protein
–Sepharose (Zymed) before separation by 7.5% SDS–PAGE. After
ransfer to Immobilon-P membrane (Millipore), phosphorylated
roteins were revealed with the anti–phosphotyrosine antibody
G10 (Upstate Biotechnology Inc., Lake Placid, NY) followed by
nhanced chemiluminescence using an ECL kit (Amersham). Blots
ere stripped according to the Amersham protocol and reprobed
ith precipitating antibody.
RESULTS
Distribution of Extracellular Matrix Components
and a6 and b1 Integrins within Virgin
Mammary Gland
The end buds and ducts of normal virgin mammary
glands are surrounded by a sheath of ECM containing both
laminin and collagen IV (Figs. 1A–1D). Laminin-1 was
adjacent to the end buds as it was recognised both by the
anti-laminin-1 antibody and by the anti-laminin a1 chain
antibody raised against its E3 domain. Collagen IV was
present at the end bud tips, although it was thinner in this
region. The only previous study carefully examining the
distribution of ECM proteins around end buds, rather than
other types of mammary epithelial structures, did not
detect basement membrane components around the distal
end bud region (Sonnenberg et al., 1986), but our investiga-
ions using confocal microscopy indicate that the proteins
re indeed present.
Staining for b1 integrins was seen throughout the end
bud, particularly strongly at the basal surface of both the
end bud epithelium and the subtending ducts (Figs. 1E–1G).
This corresponds to the cap cell layer in end buds and the
myoepithelial cell layer of ducts (Williams and Daniel,
1983). In addition, b1 integrins were present at sites of
cell–cell interaction within the luminal epithelium, and
occasional cells within end buds were strongly stained (Fig.
1G). There was weak immunoreactivity with stromal cells.
b1 integrins have not previously been examined in mouse
mammary gland, but their localisation is similar to that
observed in human breast lobules (Zutter et al., 1990). a6
integrin was present around all epithelial cells of the
mammary gland and in the stroma (data not shown), as
s of reproduction in any form reserved.
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17b1 Integrins and Mammary MorphogenesisFIG. 1. Immunolocalisation of extracellular matrix molecules and b1 integrins in the virgin mammary gland. (A–D) Thick cryosections
(30 mm) of virgin mammary gland were stained for (A, B) the E3 domain of the laminin a1 chain, (C) laminin-1, and (D) collagen IV. (B) is
a higher power image of (A). Sections were counterstained with Hoechst 33258 (blue) to detect nuclei. Projections of 10 z-sections (3 mm
steps) obtained by confocal microscopy are shown. Note staining for (A, B) E3 in a complete sheath of basement membrane surrounding the
end bud, but not in the stroma compared (C) with laminin-1 showing staining in both the basement membrane and the surrounding stroma.
(D) Collagen IV is present in the end bud basement membrane as well as in the fibrous stroma encasing the duct. Note the lack of fibrous
stroma at the end bud tip. (E–G) Thin cryosection (7 mm) of virgin mammary gland stained (E) with Hoescht 33258 and (F) with anti-b1
ntegrin antibody. Line in (E) indicates approximate demarcation between end bud and subtending duct. (G) An enlargement of the boxed
rea in (F). Strong staining for b1 integrins is seen at the basal surface of the end bud epithelium and at sites of cell–cell interaction in the
asal layer. Luminal epithelial (LE), cap (CAP) and myoepithelial (ME) cells as well as stroma (S) are positively stained. BM, basement
embrane; FS, fibrous stroma. Bars, 50 mm (A and C); 25 mm (B, D, E, F); 20 mm (G).
Copyright © 1999 by Academic Press. All rights of reproduction in any form reserved.
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18 Klinowska et al.previously reported (Sonnenberg et al., 1986). The distribu-
ion pattern of both a6 and b1 suggests integrin involve-
ment in the interaction of mammary myoepithelial cells
with basement membrane and possibly in cell–cell interac-
tions. To further investigate the role of integrins in virgin
mammary development we required function-blocking in-
tegrin antibodies. A suitable reagent for a6 had already been
FIG. 2. Immunoreactivity of the anti-b1, anti-laminin, and anti-E3
pithelial cells were radiolabelled overnight with [35S]methionine.
mmunoprecipitated with 10 mg PS/2 (anti-a4 integrin antibody),
domain peptide antibody, or control IgG and analysed by gel ele
polyclonal anti-a4b1 antibody precipitated a similar profile of inte
CID-9 cells the identity of the bands with a lower molecular we
proteins. Neither CID-9 nor primary mammary epithelial cells expr
Thus in mammary tissue the anti-a4b1 antibody is specific for b1
r EHS matrix was separated by SDS–PAGE under reducing c
mmunoblotting with anti-laminin or anti-E3 fragment polyclon
ntibody reacts with a, b, and g laminin chains as well as the purifi
eacts only with the a1 chain or the E3 fragment. Neither antibod
indicated by arrows.raised (Sonnenberg et al., 1986), and we developed our own
antibody to mouse b1 integrin.
c
m
Copyright © 1999 by Academic Press. All rightCharacterisation of the Anti-b1 Integrin
and Anti-laminin Antibodies
Immunoprecipitation. Our polyclonal anti-b1 integrin
antibody was raised against purified mouse a4b1 integrin
Edwards and Streuli, 1999). In immunoprecipitation stud-
es using [35S]methionine-labelled K-1735 M2 melanoma
ibodies. (A) M2 melanoma cells, CID-9 cells, and mouse mammary
l amounts of TCA-precipitable counts (5 3 106 cpm/lysate) were
clonal anti-a4b1 integrin antibody, anti-b1 integrin cytoplasmic
horesis under nonreducing conditions and autoradiography. The
s to the anti-b1 integrin peptide antibody. In mammary cells and
than b1 integrin is unknown but is likely to represent precursor
a1 or a4 integrin subunits, both of which were present in M2 cells.
grins. (B, C) 0.2 mg of purified collagen IV, laminin-1 E3 fragment,
tions and analysed by silver staining (7.5% SDS–PAGE; B) or
tibodies (4.0–7.5% SDS–PAGE; C). Note that the anti-laminin
3 fragment of the laminin a1 chain, whereas the anti-E3 antibody
ows any reaction with collagen IV. Molecular weight markers areant
Equa
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ed Eells, the CID-9 mammary epithelial cell line, and primary
ouse mammary epithelial cells, this antibody precipitated
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19b1 Integrins and Mammary Morphogenesisa similar profile of integrins to an antibody raised against
the COOH domain of the b1 integrin subunit and did not
detect any other proteins (Fig. 2A). Both antibodies precipi-
tated b1-associated a integrins that migrate at ;150 kDa
nd, in M2 cells, a1 integrin (Delcommenne and Streuli,
995). a4 integrin has previously not been detected in
mammary epithelial cells (D’Ardenne et al., 1991; Delcom-
menne and Streuli, 1995) and is normally associated with
cells of haematopoietic origin (Hemler et al., 1987). We
confirmed this using PS/2, a monoclonal antibody specific
for the mouse a4 integrin subunit, which precipitated a4b1
ntegrin from M2 cells but not from CID-9 or primary
ouse mammary epithelial cells (Fig. 2A). In addition, PS/2
id not immunostain epithelial cells in sections of mam-
ary gland tissue but did stain cells within lymph nodes
data not shown). Thus, as far as we can determine, a4
integrin is not expressed in normal mammary gland. This
indicates that in this tissue, the anti-b1 integrin antibody is
pecific only for b1 integrin subunits.
Immunoblotting studies showed that the affinity-purified
nti-laminin-1 antibody recognised only laminin a, b, and g
chains in purified laminin-1 and in EHS matrix, not colla-
gen IV (Figs. 2B and 2C). Similarly, affinity-purified anti-E3
antibody detected only laminin a1 chain and purified E3
ragment, not collagen IV or other laminin chains (Figs. 2B
nd 2C).
Effects on cell adhesion in vitro. The anti-b1 integrin
ntibody blocked adhesion of both first-passage mouse
ammary epithelial cells and a mammary epithelial cell
FIG. 3. Anti-b1, anti-laminin, and anti-E3 antibodies block ma
antibody blocks cell adhesion to basement membrane but not strom
laminin. Secondary mouse mammary epithelial cells (MEC), CID-9
indicated concentrations of (A, B) anti-b1 integrin or control IgG (
dishes coated with (A) basement membrane components, i.e., EHS
collagen I, fibronectin, vitronectin; or (C) laminin. After the dishes
solubilised and the absorbance was read at 595 nm. Adhesion is plo
Bars in (A, B) indicate SEM.ine to a reconstituted basement membrane matrix (EHS
atrix) and to its purified components, laminin-1 and
Copyright © 1999 by Academic Press. All rightollagen IV (Fig. 3A). The antibody also partially blocked
dhesion to the stromal ECM protein, collagen I, but had no
ffect on the adhesion of mammary cells to fibronectin or
itronectin, possibly because the cells on these substrata
dhered via b3 integrins (Fig. 3B). Addition of anti-b1
ntegrin antibody, with or without lyophilisation and resus-
ension, to subconfluent monolayers of CID-9 cells caused
ells to detach from basement membrane, fibronectin,
ollagen I, or bovine serum albumin coated coverslips (data
ot shown). Cells did not detach in the presence of control
gG or with no antibody added. Thus, this reagent is a novel
unction-blocking antibody specific for mouse b1 integrins,
nd it both interferes with attachment of mammary cells to
CM proteins and disrupts established adhesion of cells in
ulture.
The anti-laminin-1 and anti-E3 antibodies blocked adhe-
ion of mammary epithelial cells to purified laminin (Fig.
C) but not to collagen IV (data not shown). GoH3 anti-a6
ntegrin antibody has previously been demonstrated to have
unction-blocking activity (Sonnenberg et al., 1988), which
e have confirmed in studies with T47D mammary epithe-
ial cells (data not shown).
Antibody release from Elvax pellets. To study the ef-
ects of the anti-integrin and anti-laminin antibodies on
evelopment in vivo, each was separately incorporated into
low-release plastic (Elvax) pellets and implanted into the
eveloping mouse mammary gland (Silberstein and Daniel,
982). To determine antibody release kinetics, and to test
ctivity on release, a pellet containing approximately 300
ry cell adhesion to extracellular matrix. (A, B) Anti-b1 integrin
atrices. (C) Anti-laminin and anti-E3 antibodies block adhesion to
SK-7 cells were incubated for 60 min at 37°C in the presence of the
ated by c400) or (C) anti-laminin or anti-E3 antibodies in 96-well
ix, purified laminin-1, or collagen IV; (B) stromal components, i.e.,
e washed, adherent cells were stained with crystal violet and then
as a percentage of maximum in the absence of inhibiting antibody.mma
al m
, or F
indic
matr
wermg anti-b1 integrin IgG was placed in 100 ml PBS and
incubated at 37°C. The PBS was replaced every day. These
s of reproduction in any form reserved.
a20 Klinowska et al.FIG. 4. The presence of anti-b1 integrin antibody reduces the number of end buds in the virgin mammary gland of (A–C) ICR or (D–G)
MF1 mice. (A, B, D, E, F) Photomicrographs of whole-mounted glands after 6 days in the presence of (A, D) control IgG or (B, E) anti-b1
ntibody or (F) with no implant, stained with haematoxylin. Asterisks indicate end buds, P indicates pellet, LN indicates lymph node. In
Copyright © 1999 by Academic Press. All rights of reproduction in any form reserved.
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21b1 Integrins and Mammary Morphogenesisextracts were then used to immunoprecipitate integrins
from [35S]methionine-labelled CID-9 cell extracts. In this
solution assay, the majority of integrin antibody was re-
leased within 1 day and continued to be released for at least
a further day (data not shown).
To examine antibody release and distribution in vivo,
Elvax pellets containing the different antibodies or their
controls were implanted into the No. 4 mammary glands of
5-week-old mice, close to or just in front of the advancing
end buds. Cryosections of glands harvested at various times
after implantation were stained by immunofluorescence
using an FITC–conjugated secondary antibody (data not
shown). All the antibodies tested were still present in the
implanted glands after 6 days and showed a uniform distri-
bution throughout the gland. Control IgG was present
throughout the mammary gland, but was diffuse and did
not stain any particular area of the tissue. In contrast,
anti-b1 integrin IgG was strongly localised to the basal
urfaces of ductal epithelium, indicating that the anti-b1
ntegrin antibody crossed the basement membrane and
ontacted the epithelial cells. Antibody was not seen in the
ontralateral unimplanted gland and therefore did not ap-
ear to enter the bloodstream. The antibody was eventually
leared from the mammary gland, since no IgG was de-
ected using this method 10 days after implantation. In
imilar experiments performed with pellets containing
nti-a6 integrin or anti-laminin antibodies, staining was
ocalised to the surface of epithelial cells and to the base-
ent membrane, respectively.
Together our data indicate that all the antibodies used in
his study are function-blocking since they block mammary
ell adhesion in vitro, and their adhesion-perturbing effects are
ubstrate specific. Antibody is released from Elvax pellets in
n active state in vitro and is able to penetrate the mammary
gland in vivo and localise to epithelial cells in regions where
ntegrins are associated with cell–ECM interactions.
Anti-b1 Integrin Antibody Dramatically Alters
ammary Gland Morphogenesis in vivo
End bud number. To determine the effect of function-
blocking anti-b1 integrin antibody on mammary gland mor-
hogenesis in vivo, one of the fourth (abdominal) pair of
ammary glands of 5-week-old mice was implanted with an
lvax pellet containing approximately 300 mg anti-b1 integrin
ntibody. Contralateral No. four glands were implanted with
ontrol rabbit IgG or were left unimplanted. In the first set of
(E), the implanted pellet was located to the bottom left of the lymp
(C, G) Graphs showing the effect of Elvax pellets containing anti-b1
per mammary gland in virgin (C) ICR or (G) MF1 mice compared w
statistically significant differences by Student’s T test. ICR and MF.01), and day 6 b1 vs day 6 IgG (0.05 . P . 0.01). MF1 day 20 b1 vs
are 29, 8, 8, 6, 6, 6, and 5, respectively, for ICR and 49, 11, 10, 9, 10, 1
Copyright © 1999 by Academic Press. All rightxperiments the ICR mouse strain was used. Pellets were left
n place for up to 6 days before the glands were removed for
hole-mounting and haematoxylin staining (Figs. 4A and 4B).
he number of end buds in control and anti-b1 integrin
implanted mammary glands was quantitated. Compared to
the number at day 0, the start of the experiment, a dramatic
(48%) reduction in the number of end buds was seen after 3
days with anti-b1 integrin antibody (P , 0.001; Fig. 4C). In
ddition, compared with IgG, a 39% reduction in the number
f end buds at day 3 and day 6 of anti-b1 integrin implantation
was observed (0.05 . P . 0.01).
The mammary gland ductal network expands over this
6-day period (from postnatal day 35 to 41) to fill the fat pad
more completely, but in ICR mice the number of end buds
remained fairly constant during this time and was not
significantly affected by control IgG (Fig. 4C, compare end
bud number with no implant on day 0 with that on day 6).
However, throughout this time there were fewer end buds
in the presence of antibody, indicating that inhibiting
integrin function caused a decrease in end bud number.
This reduction in end bud number did not appear to be
localised to the immediate vicinity of the pellet. End buds
that remained were seen close to the pellet (Fig. 4B) and
further away from it (Fig. 4E).
To examine whether the results were strain dependent and
to extend our data, we repeated these experiments using MF1
mice. A similar b1-integrin-dependent inhibition of end buds
as observed. Results similar to those using the ICR strain
ere obtained (Figs. 4D–4G). In contrast to ICR, end bud
umber in MF1 mice doubled between postnatal days 35 and
7 before declining and was not statistically affected by the
resence of normal IgG (see Fig. 4G; no implant and IgG bars).
gain a reduction in the number of end buds after 3 days
reatment with anti-b1 integrin IgG was observed (41% of
hose at day 0, P , 0.001). The number of end buds was
educed in comparison to the normal IgG controls by 47% on
ay 3 and 46% on day 6 post-pellet implantation (0.05 . P .
.01). So in MF1 mice as well as in ICRs, we have demon-
trated that blocking b1 integrin function results in the
egression of existing end buds as well as the inhibition of new
nd bud formation.
It is important to note that anti-b1 integrin antibody did
ot affect the overall integrity of the ductal network within
he mammary gland; its action appeared specific and af-
ected only end buds. We also discovered that the inhibition
as transient since 12 days after pellet implantation the
land began to recover. We had already shown that at 12
de and was just out of frame of the photograph. Scale bar, 900 mm.
rin antibody or preimmune IgG on the average number of end buds
unimplanted glands over up to 20 days in vivo. Asterisks indicate
y 3 with b1 pellet vs day 0 (P , 0.001) and day 3 IgG (0.05 . P .h no
integ
ith
1 da
day 20 IgG (0.05 . P . 0.01). Numbers of glands in each group
0, 7, 4, 4, 4, 4, 4, and 4 for MF1. Bars indicate SEM.
s of reproduction in any form reserved.
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22 Klinowska et al.days, the antibody was depleted from the gland, as it was
not detected by immunofluorescence. In MF1 mice, the end
bud number with anti-b1 integrin implanted for 12 days
was only fractionally lower than that of IgG controls (Fig.
4G). By 20 days postimplantation, glands with anti-b1
ntegrin antibody still had a large number of end buds,
ndicating their continuing recovery from growth inhibi-
ion in the presence of antibody. By contrast, end buds in
he IgG implanted controls had regressed, leaving only
erminal ductal structures, since insufficient gland-free
troma remained for continued ductal elongation. In further
xperiments to examine the effect of using higher doses of
ntibody (600 mg per implant) for up to 3 days, we found
hat a similar (approximately 50%) amount of inhibition of
rowth was seen (data not shown). Since our antibody is
olyclonal, future experiments to test whether monoclonal
nti-mouse integrin antibodies inhibited end bud structures
ompletely would be beneficial. No significant effect earlier
han 3 days post-pellet implantation was observed by
hole-mount analysis or in H&E-stained sections.
Extent of mammary ductal network. To assess the ex-
ent of the ductal network, the distance from the middle of the
entral lymph node of the gland to the tip of the furthest
igrated duct was measured on whole-mounted mammary
lands. We found that the decrease in the number of end buds
een at 6 days post-pellet implantation (Fig. 4) translated into
decrease in the extent of the ductal network several days
fter this (Fig. 5, day 12; compare b1 integrin with IgG and no
mplant). The recovery in the number of end buds seen at day
2 in the anti-b1 integrin-treated glands (Fig. 4G) was reflected
y a subsequent recovery of the extent of the ductal network
o control levels by day 20 postimplantation (Fig. 5). This
FIG. 5. The presence of anti-b1 integrin antibody reduces the
xtent of the mammary ductal network. Graph showing the effect
f Elvax pellets containing anti-b1 integrin antibody or control IgG
on the extent of the ductal network in virgin MF1 mice compared
with unimplanted glands over 20 days in vivo. Bars indicate SEM.
Numbers of glands in each group are 11, 10, 3, 11, 8, 7, 4, 4, 3, 4, 2,
and 2, respectively.upports the current view that ductal elongation occurs
hrough proliferation of cells in the end bud and extension at
i
m
Copyright © 1999 by Academic Press. All righthis region. Since end bud number recovers at around this
ime (Fig. 4G), we would expect this to be reflected in an
ncreased ductal network several days later, and indeed this is
hat was observed (Fig. 5; compare b1 integrin with IgG or
control on day 20).
Together, the in vivo morphological studies indicated
that the anti-b1 integrin antibody caused end buds to
regress significantly up to 6 days postimplantation, leading
to a measurable difference in the elongation of the ductal
network by day 12. As the antibody in glands implanted
with Elvax pellets became depleted, the glands recovered
and the final extent of growth appeared normal.
Although the anti-a4 integrin component of the poly-
lonal anti-a4b1 serum should not affect mammary cells as
hey do not express a4, it may have affected other struc-
ures within the gland since, for example, a4 integrin is
expressed on the surface of circulating lymphocytes. To
control for this possibility, pellets containing 300 mg PS/2 (a
function-blocking monoclonal anti-mouse a4 integrin anti-
ody) or control rat IgG2b were implanted into the mam-
ary glands of 5-week-old mice, exactly as before, and left
or 6 days. No effect on the number of end buds or on the
istance of ductal migration was observed (data not shown).
Taking these results together we conclude that functional
b1 integrins are required for maintenance of end bud structure
and morphological development of the mammary gland.
Implanted Glands Display No Obvious Differences
in Cellular Organisation, Proliferation,
or Apoptosis
Our data show that implanting anti-b1 integrin antibody
into developing mammary gland produced obvious macro-
scopic effects and we therefore attempted to determine the
mechanism underlying these changes using several ap-
proaches. It was possible that the antibody caused an
inflammatory reaction in the gland or alternatively it might
have increased apoptosis or decreased cell proliferation in
developing end buds, thereby causing them to regress.
H&E-stained paraffin sections of glands implanted with
anti-b1 integrin antibody showed no obvious infiltration of
nflammatory cells, indicating that the effects on ductal
orphology were unlikely to be due to an immune re-
ponse. The lack of PS/2 staining in treated glands also
onfirmed the absence of lymphocytes (data not shown).
At the cellular level, no gross differences in morphology
ere observed by H&E staining in the end buds of control
nimals or in the remaining end buds of anti-integrin-
reated glands (Figs. 6A and 6B). End buds did not show a
isrupted organisation of cells as they do in the presence of
nti-cadherin antibody (Daniel et al., 1995). The tube
ithin a tube structure of myoepithelial cells surrounding
he epithelial core was retained in treated and control tissue
Figs. 6C and 6D). In fact, in the end buds that remained
here was no obvious difference in morphology and no
ncrease in the thickness or distribution of the surrounding
atrix. Immunofluorescent staining of cryosections of
s of reproduction in any form reserved.
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23b1 Integrins and Mammary Morphogenesisglands with antibodies against E-cadherin (ECCD-1) and a6
integrin (GoH3) showed no difference in the distribution of
these markers in tissue implanted with anti-b1 antibody
ompared with controls (data not shown). Glands im-
lanted with anti-b1 integrin antibody also showed similar
cell proliferation (as shown by BrdU incorporation; Fig. 6E)
and apoptotic indices (as shown by apoptotic figures seen in
H&E-stained sections; Fig. 6F) in end buds compared with
unimplanted or IgG implanted glands. These results suggest
that in the structures we have been able to analyse, the
anti-b1 integrin antibody did not affect proliferation or
poptosis. Therefore, to examine the effect of anti-b1 inte-
FIG. 6. Treated glands have no obvious inflammatory infiltrate,
do not exhibit any aberrant organisation of cells, and do not show
altered levels of proliferation or apoptosis in end buds. H&E-
stained paraffin sections of (A, C) anti-b1 antibody or (B, D) control
IgG-treated glands. Black arrows indicate myoepithelial cells.
White arrows indicate apoptotic cells. Graphs showing the effect of
anti-b1 antibody or control IgG on (E) the proliferation and (F)
apoptotic indices in end buds of virgin MF1 mice compared with
unimplanted glands over 6 days in vivo. Proliferation and apoptotic
indices were calculated as the percentage of BrdU labelled cells or
apoptotic figures to the total number of nuclei within the end bud
sections. Bars indicate SEM. Numbers of end buds counted for each
group were (E) 36, 29, and 32 and (F) 18, 13, and 18, respectively.rin antibody in more detail, we switched to an in vitro
odel of mammary ductal development.
Copyright © 1999 by Academic Press. All rightAnti-b1 Integrin Antibody Perturbs Tubulogenesis
f Mammary Cells in Culture
Extensive branching morphogenesis of TAC-2 mouse mam-
mary epithelial cells can be induced in three-dimensional
collagen gel culture where the cells deposit their own laminin-
containing basement membrane in response to HGF and form
elaborately arborised tubules (Soriano et al., 1995). We there-
fore assessed whether anti-b1 integrin antibody could affect
this tubulogenic process. Addition of increasing concentra-
tions of anti-b1 integrin antibodies to TAC-2.1 cells grown in
he presence of HGF resulted in a progressive inhibition of
ube formation (Fig. 7). At 50 mg/ml the anti-b1 integrin
antibody totally suppressed morphogenesis, resulting in the
formation of spherical cell colonies (Fig. 7F). Quantitative
analysis demonstrated that the anti-b1 integrin antibody in-
duced a significant (P , 0.001) dose-dependent decrease in
otal cord length (Fig. 7G).
We also examined whether the anti-b1 integrin antibody
could inhibit spontaneous cord formation. When suspended
in collagen gels in the absence of HGF, TAC-2.1 cells
formed small colonies with morphologies ranging from
spherical aggregates to short, poorly branched cords (Sori-
ano et al., 1996). Incubation with increasing concentrations
of anti-b1 integrin antibody resulted in a dose-dependent
inhibition of spontaneous cord elongation (Fig. 7G). In
addition, the anti-tubulogenic activity of the anti-b1 inte-
grin antibody was not restricted to TAC-2 cells, since it
inhibited spontaneous cord formation by two distinct sub-
clones (Montesano et al., 1998) of the EpH4 mammary
epithelial cell line (Fialka et al., 1996; data not shown).
Our results in vivo suggested that as antibody became
depleted from the gland, the number of end buds and the
extent of the ductal network recovered. We therefore as-
sessed whether the inhibitory effect of the anti-b1 integrin
antibody was also reversible in the culture model. TAC-2
cells were grown for 6 days in the presence of HGF to allow
the formation of branched cords (Figs. 8A and 8B), at which
time anti-b1 integrin antibody was added to the cultures.
This induced the retraction of cell cords towards the centre
of the colony (Figs. 8C and 8D), resulting in the formation of
stubby cords (Fig. 8E) or rounded cell aggregates (Fig. 8F).
Cord formation resumed promptly after antibody washout
(Figs. 8G and 8H), giving rise to thick, branched cords with
a three-dimensional morphology similar to that of the
original colonies, thus demonstrating the reversibility of
the antibody effect.
Together these data show that in a culture model of
mammary tubulogenesis that closely mimics the formation
of ducts in vivo, functional b1 integrins are required for
duct formation. This effect was reversible both in vivo and
n the culture model.
Anti-b1 Integrin Antibody Does Not Affect
yrosine Phosphorylation of the c-Met Receptor
Mammary morphogenesis is dependent not only on b1
integrins but also on HGF, both in vivo (Yang et al., 1995)
s of reproduction in any form reserved.
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24 Klinowska et al.and in the culture model (Soriano et al., 1995; Fig. 8). Since
mammary cell interactions with the ECM affect the ability
of soluble ligands such as prolactin and insulin to trigger
their downstream intracellular phosphorylation cascades
(Edwards et al., 1998; Farrelly et al., 1999), we asked
FIG. 7. Antibody against b1 integrins inhibits the tubulogenic act
9 days in the presence of (A, D) 10 ng/ml HGF alone, (B, E) HGF and
integrin antibody. Note that TAC-2.1 cells incubated with HGF al
antibody results in a marked reduction in cord length. Addition
orphogenesis and results in the formation of spherical cell colon
effect of anti-b1 antibody. TAC-2.1 cells in collagen gels incubate
nti-b1 integrin antibody (filled circles) or control IgG (filled square
alone (open triangle). In each of at least three separate experiments,
length of all cords in each field was determined as described undewhether integrin function was required for HGF to trigger
tyrosine phosphorylation of its cell surface receptor, c-Met. r
Copyright © 1999 by Academic Press. All rightAC-2.1 cells grown in monolayer culture on collagen were
timulated for 15 min with HGF after incubation for up to
4 h with anti-b1 integrin antibody. Phosphorylation of the
c-Met receptor was rapid and sustained, occurring within 6
min of HGF treatment (Fig. 9A). TAC-2 cells cultured in
of HGF. TAC-2.1 cells suspended in collagen gels were grown for
g/ml anti-b1 integrin antibody, or (C, F) HGF and 10 mg/ml anti-b1
orm branching cords, but that addition of 2 mg/ml anti-b1 integrin
0 mg/ml anti-b1 integrin antibody totally suppresses branching
ars, 500 mm (A–C); 200 mm (D–F). (G) Quantitative analysis of the
r 9 days with 10 ng/ml HGF and the indicated concentrations of
i-b1 integrin antibody alone (inverted open triangle), or control IgG
randomly selected fields were photographed, and the total additive
terials and Methods.ivity
2 m
one f
of 1
ies. B
d fomonolayer with 50 mg/ml anti-b1 integrin antibody became
ounded, but at this concentration of antibody they did not
s of reproduction in any form reserved.
cn
lone
. 24
25b1 Integrins and Mammary Morphogenesisdetach from the substratum. Under these conditions, ty-
FIG. 8. The effect of anti-b1 integrin antibody is reversible. (A, B) T
g/ml HGF alone for 6 days. At this time 50 mg/ml anti-b1 integrin
multicellular structures as those shown in (A, B) were photographed af
washed out, and cultures were further incubated with HGF alone for 24
during the experiment. Note that TAC-2.1 cells incubated with HGF a
resulted in a marked reduction in cord length and branching after 12 h
200 mm.rosine phosphorylation of c-Met was still evident after HGF
treatment (Fig. 9B), and similar results were also seen when
i
Copyright © 1999 by Academic Press. All rightells were grown in collagen gels in the presence of anti-b1
.1 cells suspended in collagen gels were grown in the presence of 10
body, together with HGF, was added to the cultures, and the same
, D) 12 h or (E, F) 24 h. (G, H) After 24 h the antibody was extensively
, C, E, G) and (B, D, F, H) show the progress of three different colonies
formed branching cords, whereas addition of anti-b1 integrin antibody
h after antibody withdrawal, elongation and branching resumed. Bar,AC-2
anti
ter (C
h. (Antegrin antibody (data not shown).
These findings indicate that at least the proximal signal-
s of reproduction in any form reserved.
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26 Klinowska et al.ling event in this pathway was integrin-independent. An
alternate possibility is that rather than being required for
signal transduction pathways involved in morphogenesis,
b1 integrins may be necessary to promote physical interac-
tions between mammary cells and their ECM. Indeed,
closer inspection of Fig. 8 indicates that following integrin
antibody washout, the cells formed cords along preformed
pathways within the collagen gel (compare Figs. 8A and 8B
with 8G and 8H). In addition, antibody treatment caused
retraction of the cords into spherical aggregates, rather than
just stasis of morphogenesis, suggesting a complete failure
of adhesion.
Anti-a6 Integin Antibody Has No Effect
n End Bud Number
To examine the role of potential a subunit partners for b1
ntegrin, pellets containing anti-a6 integrin monoclonal
antibody were implanted into developing mammary glands
as before. Blocking the function of a6 integrin had no
significant effect on the number of end buds 24 h, 3 days, or
6 days after pellet implantation (Fig. 10A), nor was the
morphology of the gland affected as determined by whole-
mount analysis (Figs. 10B and 10C) or in H&E-stained
sections (data not shown). We therefore conclude that
either a6 is not the crucial partner for b1 integrin in this
ystem or alternatively that several a-b1 heterodimers are
FIG. 9. Anti-b1 integrin antibody does not affect tyrosine phos-
horylation of the c-Met receptor. TAC-2.1 cells were grown on
ollagen to subconfluency, serum-starved overnight, and treated
A) with 20 ng/ml HGF for increasing lengths of time or (B) with 50
mg/ml anti-b1 integrin or control IgG for 0–24 h and HGF for 20
min. Cell lysates were immunoprecipitated with anti-c-Met anti-
body, separated by 7.5% SDS–PAGE and analysed by immunoblot-
ting with antibodies for phosphotyrosine (4G10) or the appropriate
precipitating antibody. The c-Met receptor was phosphorylated 6
min after HGF stimulation and remained phosphorylated after 2 h.
50 mg/ml anti-b1 integrin antibody did not affect c-Met phosphor-
ylation in response to HGF.involved and blocking the function of a6 alone is not
sufficient to affect mammary development.
Copyright © 1999 by Academic Press. All rightAnti-laminin Antibody Reduces End Bud Number
while Anti-E3 Antibody Has No Effect
on Mammary Morphogenesis
Since b1 integrin was required for normal mammary
gland morphology, we wanted to examine whether a
potential ligand was also required. Thus, pellets contain-
ing 300 mg affinity-purified polyclonal antibody raised to
aminin-1 were implanted into developing mammary
lands as before. A significant reduction in the number of
nd buds was seen after 24 h and 3 days (45 and 71%,
espectively; P , 0.01). However, 6 days after pellet
mplantation development of the gland had returned to
ormal (Fig. 10D). No disruption in the cellular organi-
ation of the mammary gland was seen in H&E-stained
araffin sections of treated glands (data not shown). In
ontrast to the results obtained with the anti-laminin
ntibody, pellets containing 300 mg affinity-purified
nti-E3 antibody had no effect on mammary development
Fig. 10E). These results suggest that laminin is an
mportant extracellular matrix ligand during ductal de-
elopment. However, although it is possible that the
nti-E3 antibody was unable to fully access the necessary
pitopes within the mammary tissue, our data suggest
hat it is not the E3 component of the a1 chain that is the
rucial domain of the laminin trimer in this system. The
imilarity in phenotype observed between glands treated
ith anti-b1 integrin and anti-laminin antibodies indi-
cates that both laminin and b1 integrin are crucial to end
bud persistence and ductal elongation in the developing
mammary gland.
DISCUSSION
This is the first demonstration that both b1 integrin and
aminin are required for the normal morphogenesis of virgin
ammary ductal epithelium during pubertal development
n vivo. Such experiments have not previously been pos-
ible due to the lack of function-blocking anti-mouse inte-
rin reagents. The anti-b1 integrin antibody blocked adhe-
sion of primary mammary cells to basement membrane
proteins in culture and disrupted preestablished adhesion of
primary cells cultured on ECM proteins. However, it did
not affect proliferation or apoptosis of mammary cells in
vivo or alter the proximal tyrosine phosphorylation events
induced by the mammary morphogenetic growth factor
HGF. Since the anti-b1 integrin antibody became localised
to sites of cell–basement membrane interaction in vivo, we
suggest that it may perturb morphogenesis via an effect on
cellular traction through the ECM. The observation that
mammary cells cultured within collagen gels undergo mor-
phogenesis along preformed pathways following removal of
the b1 integrin antibody supports this hypothesis. How-
ever, the inhibitory effect on development in mammary
tissue was specific to end buds since the rest of the gland
architecture remained intact, indicating that the antibody
did not have a general adhesion-blocking phenotype in vivo.
s of reproduction in any form reserved.
g
S
p
u
a
r
a
i
c
S
C e pre
indic
27b1 Integrins and Mammary MorphogenesisThe finding that blocking laminin function in vivo pro-
duced a similar phenotype suggests that both laminin and
b1 integrin are crucial to ductal morphogenesis.
b1 Integrins and Laminin Are Required for
Mammary Gland Development in Vivo
The observation that b1 integrin null mice die in early
embryogenesis underscores the crucial role of the b1 inte-
rin family in morphogenesis (Fassler and Meyer, 1995;
tephens et al., 1995). However, a study of b1 integrin
FIG. 10. The presence of anti-laminin antibody reduces the num
ntibodies to a6 integrin or the E3 domain of laminin-1 have no e
ntegrin, (D) anti-laminin, or (E) anti-E3 domain antibodies on the
ompared with pellets containing control IgG over 6 days in vivo (7
tudent’s T test (P , 0.01). Numbers of animals in each group are
) Photomicrographs of whole-mounted glands after 3 days in th
haematoxylin. Asterisks indicate end buds, P indicates pellet, LNfunction in the mammary gland using this technique has
not yet been possible since the tissue largely develops
Copyright © 1999 by Academic Press. All rightostnatally. Our rationale of using antibodies has allowed
s to overcome this problem and offers a complementary
pproach to gene knockout in which compensatory up-
egulation of related genes can mask phenotypic changes.
One previous study has examined the role of b1 integrins
in mammary gland function in vivo (Faraldo et al., 1998). In
that case, the development of mature mammary gland,
particularly during pregnancy, was perturbed following ex-
pression of a dominant negative b1 integrin transgene
expressed under the control of the MMTV promoter. In the
pregnant gland, decreased cell proliferation, increased
f end buds in the virgin mammary gland of mice in vivo, whereas
Graphs showing the effect of Elvax pellets containing (A) anti-a6
age number of end buds per mammary gland in virgin MF1 mice
for E3). Asterisks indicate statistically significantly differences by
1, 11, and 7; (D) 7, 8, and 7; (E) 9, 17, and 7. Bars indicate SEM. (B,
sence of (B) anti-a6 antibody or (C) control IgG2a, stained with
ates lymph node. Scale bar, 900 mm.ber o
ffect.
aver
days
(A) 1apoptosis in alveoli, and reduced milk protein expression
were observed. However, development of the ductal net-
s of reproduction in any form reserved.
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28 Klinowska et al.work in pubertal mammary gland was unaffected in these
mice, probably due to low MMTV promoter activity at this
time. One key difference in the cellular architecture of the
mammary alveolus during pregnancy compared with that of
the end bud or the ductal epithelium is that during preg-
nancy the secretory epithelial cells are in direct contact
with the basement membrane rather than being separated
from it by a continuous layer of myoepithelial cells. We
have previously identified roles for b1 integrin in the
function of mammary cells from pregnant mice using
culture models (Streuli et al., 1991; Farrelly et al., 1999),
and this has been backed up by the in vivo studies in
pregnancy (Faraldo et al., 1998). Our new data support their
conclusion that b1 integrins are required for mammary
land function in vivo. However, they extend it by demon-
trating that integrins have roles during additional stages of
evelopment, in particular for the maintenance of end bud
tructure in puberty. Moreover our data suggest that a b1
integrin ligand, laminin-1, is also required for maintenance
of mammary end buds.
The identity of the important a integrin subunit in
mammary ductal development in vivo has not yet been
established, but our data suggest that it is unlikely to be a6
ntegrin. A number of other a integrin subunits, including
a2 and a3 but not a1 or a7, are expressed in the mammary
land during development (Delcommenne and Streuli,
995; Oliver et al., manuscript in preparation). Therefore
ne possibility is that several a subunits may be involved in
ammary morphogenesis, but inhibiting the function of a
ingle a subunit may allow others to substitute. An alter-
nate approach to identifying which a subunit(s) is involved
in mammary morphogenesis comes from transplanting in-
tegrin subunit-null tissue into the mammary fat pads of
wild-type syngeneic hosts, and such investigations are
currently being performed in this laboratory (Klinowska et
al., manuscript in preparation).
Complementary to the role for integrin in the mainte-
nance of end buds is our observation that the anti-laminin-1
antibody blocks mammary morphogenesis. Interestingly,
the anti-E3 antibody does not have this effect even though
it is effective in blocking adhesion of mammary cells to
laminin in culture. The anti-laminin-1 antibody contains
reactivity towards the g1 chain that is present in many
laminin species, while the anti-E3 antibody is specific for
the a1 chain. We have preliminary data that laminin-1,
aminin-3, laminin-5, and laminin-10 are expressed in the
asement membrane of mammary epithelium (Oliver et al.,
anuscript in preparation), and of these only laminin-1 and
aminin-3 contain the a1 chain. It is therefore possible that
aminins other than laminin-1 are important for mammary
orphogenesis, but confirmation of this must await devel-
pment of appropriate function-blocking antibodies or con-
itional knockout mice.
Important differences are observed in the integrin–ECM
nteractions in different developing systems. For example,
ntibodies to a6 integrin and the E3 fragment of laminin-1
lock development of the embryonic kidney (Sorokin et al.,
l
1
Copyright © 1999 by Academic Press. All right990, 1992) and of salivary glands (Kadoya et al., 1995) in
ulture. However, the developing mammary gland in vivo
oes not appear to require functional E3 or a6 integrin alone
for ductal morphogenesis (Figs. 10A and 10E). These data
underscore the importance of studying different develop-
mental systems to achieve a synthesis of morphogenetic
mechanisms.
Problems Associated with Identifying a
Morphogenetic Mechanism for b1 Integrin
Requirement Using the in Vivo System
Elucidating a mechanism for the requirement of b1
integrins in ductal growth remains an important goal,
although this is particularly difficult in vivo. In the virgin
end bud, only cap cells and myoepithelial cells are in direct
contact with the basement membrane, here demonstrated
to contain both laminin-1 and collagen IV (Fig. 1). Thus the
function-blocking anti-b1 integrin antibody may act di-
ectly on cell–basement membrane interactions.
Integrins are required for the survival and proliferation of
dherent cells. In cultured mammary epithelial cells, a6
and b1 integrin antibodies induce apoptosis of isolated
luminal cells derived from pregnant mice (Boudreau et al.,
1995; Pullan et al., 1996; Farrelly et al., 1999). In the virgin
gland, specific cells within the end buds undergo apoptosis
during normal mammary development (Humphreys et al.,
1996). The apoptotic cells were several cell diameters from
the underlying ECM, suggesting that they may have been
deleted due to lack of integrin-mediated survival signals as
in the case of embryonic cavitation (Coucouvanis and
Martin, 1995). Furthermore, a twofold increase in apoptosis
of mammary cells in pregnancy was observed when integrin
function was perturbed by a dominant-negative transgene
(Faraldo et al., 1998). We therefore reasoned that the anti-
ntegrin antibody might increase apoptosis in the remaining
nd buds in vivo after antibody treatment, but found no
ffect of the presence of function-blocking b1 integrin
antibody. In addition, the cultured TAC-2.1 cell clusters
remaining within collagen gels after antibody treatment
underwent morphogenesis after antibody withdrawal, indi-
cating that if any apoptosis had occurred it was to a limited
degree. Thus, the b1 integrin antibody does not appear to
block morphogenesis via induction of apoptosis, which is
consistent with our observation that its inhibition is revers-
ible. One possibility is that differentiated mammary cells
from pregnant mammary gland (Faraldo et al., 1998; Pullan
et al., 1996) may be more dependent on ECM survival cues
than cells from the less differentiated virgin mammary
tissue, as has been shown for other cell types (Globus et al.,
1998).
The current model of growth in the virgin mammary
gland has been elucidated from studies on the effect of
implants containing TGFb1, 2, or 3, where end buds shut
own and assume the morphology of terminal ducts, with
ittle cell proliferation detectable (Silberstein and Daniel,
987; Robinson et al., 1991). However, these structures
s of reproduction in any form reserved.
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29b1 Integrins and Mammary Morphogenesisretain the capacity to become end buds and reemerge once
TGFb is removed. The morphological effect of anti-b1
integrin or anti-laminin antibodies on virgin ductal devel-
opment is reminiscent of, but most likely different from,
that of TGFb. Analysis of total end bud number reveals that
not only are new end buds prevented from forming but
existing end buds must also regress. In contrast to the TGFb
studies, in which a thick collagenous sheath was deposited
around the end bud physically inhibiting growth (Silber-
stein et al., 1990), we did not observe massive ECM depo-
sition by light microscopy in the presence of b1 integrin or
laminin antibodies. It was therefore not possible to distin-
guish between end buds that had regressed through the
action of anti-integrin antibody from those that had re-
gressed naturally. A further caveat is that although we have
shown that all the antibodies used are function-perturbing
in culture some may be less effective in vivo.
Despite extensive investigation, we have been unable to
pinpoint a mechanism by which blocking the function of b1
integrins affects the development of virgin mammary gland.
The most likely explanation is that the inhibition of b1
integrins occurs at random within the end bud population
and we are simply not observing any end buds during their
regression. So although anti-b1 integrin antibody does not
appear to have a significant effect on cell proliferation or
survival within the end buds that remain in treated glands,
it may be that proliferation and cell survival are affected in
structures that would have been end buds had the function
of b1 integrins not been blocked.
A Possible Role for b1 Integrin Based
on Culture Studies
To simplify investigation of the mechanism by which
anti-b1 integrin antibody exerts its effect on glandular
evelopment, we used a 3-D collagen gel model in which
ultured cell lines undergo morphogenesis under the influ-
nce of factors such as HGF (Soriano et al., 1995). The
cords” that form in the culture model differ from mam-
ary ducts in vivo, notably in the absence of a complex end
ud structure. It has so far not been possible to maintain
nd bud morphology in vitro (Daniel et al., 1984; Richards
t al., 1982); however, elegant studies using end bud cells
mbedded in collagen and subsequently implanted in vivo
ave demonstrated that cord morphologies were seen while
ells remained in contact with collagen, but that end bud
tructures formed as soon as cells grew into adipose tissue
Daniel et al., 1984). Thus the cord morphology may be a
implified form of morphogenesis; it is not an artefact of
ulture, but instead may be due to direct contact with
ollagen I rather than the mammary stroma. In addition,
ords of TAC-2.1 cells deposit basement membrane be-
ween the cells and the collagen gel (Soriano et al., 1995),
uggesting first that in this regard the culture model re-
embles the epithelial cell–basement membrane–stromal
atrix arrangement seen in vivo, and second, that the
nti-b1 integrin antibody may directly affect cell–basement
Copyright © 1999 by Academic Press. All rightembrane adhesion in culture. Studies using cultured
uman mammary epithelial cells either derived from car-
inomas or isolated from milk have suggested a role for
a2b1 integrin in the spontaneous branching phenotype seen
n collagen gel cultures (Berdichevsky et al., 1992; Keely et
l., 1995; Saelman et al., 1995; Zutter et al., 1995). How-
ver, in these studies it was not clear whether the cells
eposited an endogenous basement membrane.
We wished to determine whether our antibody blocked
GF-induced mammary morphogenesis in culture since
GF has been shown to be important for ductal develop-
ent in vivo (Yang et al., 1995). Our findings indeed
howed that the anti-b1 integrin antibody abolished HGF-
timulated morphogenesis of cells cultured in collagen gels,
nd these results led to two possible hypotheses for the role
f b1 integrin. Initially, we postulated that integrins might
e involved in crosstalk with the c-Met HGF receptor. This
uggestion was built on our previous work demonstrating
n involvement of integrins in the tyrosine phosphorylation
vents associated with the prolactin signalling pathway
riving milk protein gene transcription (Edwards et al.,
998; Streuli et al., 1991, 1995). However, we found that
lthough tyrosine phosphorylation of the c-Met receptor
as rapidly induced after HGF stimulation, it was unaf-
ected by incubation of cells for up to 24 h with anti-b1
ntegrin antibody. Thus, the effect of blocking b1 integrin
n ductal morphogenesis must be either downstream of
-Met receptor phosphorylation or completely independent
f it.
An alternative possibility was that a key role for integrins
ight reside in the physical interaction of ductal cells with
he ECM. In this model, HGF supplies the stimulation for
rowth, while integrins provide purchase for ductal elonga-
ion. Such a hypothesis is supported by the experiments
ith function-blocking anti-b1 integrin antibody in the
culture model. Here, the ductal cords that form under the
influence of HGF retract to spherical structures in the
presence of integrin antibody, but then regrow along previ-
ously formed canals within the collagen gels after antibody
is removed (Fig. 8). These results are in broad agreement
with recent reports that altering the strength of integrin
interaction with the ECM affects HGF-induced branching
of human mammary epithelial cells in culture (Alford et al.,
1998). That system was different from ours since the
integrin-blocking antibody was added at the time of cell
plating and caused cell dissociation rather than inhibition
of morphogenesis. In addition, reduced HGF-induced mor-
phogenesis in collagen gels was observed in MDCK cells
expressing antisense a2 integrin, although here the high
evels of apoptosis induced by expression of the antisense
onstruct complicate interpretation of the results (Saelman
t al., 1995).
Thus, although there are differences between the in vivo
nd the culture models there are also important similari-
ies. In vivo, end bud number is diminished by the anti-b1integrin antibody (Fig. 4), resulting in a reduced extent of
the ductal network several days later; as the antibody
s of reproduction in any form reserved.
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30 Klinowska et al.becomes depleted, the glands recover (Fig. 5). In the culture
model, mammary epithelial cord length is reduced by
anti-b1 antibody, but cord formation resumes after anti-
ody washout. Thus, b1 integrin is required both for duct
extension in vivo and cord elongation in culture. Since end
uds do not appear to be able to be formed within collagen
els, it remains to be determined whether the precise
echanism for integrin requirement is similar in both
ystems. However, given the lack of apoptosis in both
ystems and the lack of any obvious changes to ductal
orphology in vivo, it is possible that integrins are required
or cellular traction through the stromal matrix rather than
he maintenance of normal cellular architecture.
Implications for Breast Cancer Progression
Our study has implications for deciphering breast cancer
progression, since it indicates a role for integrin in mam-
mary epithelial morphogenesis. Breast tumours have low-
ered levels of some integrin subunits. However, b1 subunit
evels are often retained (Koukoulis et al., 1991) and their
blation, for example in the aggressive MDA-MB-435 breast
arcinoma line, led to fewer and smaller metastases in
u/nu mice (Wewer et al., 1997). Moreover, breast cancer
atients with higher levels of integrin expression in their
umours had shorter survival times (Friedrichs et al., 1995).
ince anti-integrin antibodies can revert tumour cells to a
ormal phenotype (Weaver et al., 1997), and since our work
hows that they block mammary morphogenesis, we sug-
est that therapeutic strategies to target the function of b1
integrins in vivo may compromise the ability of tumour
ells to form metastatic outgrowths and thereby severely
educe progression to malignancy.
Summary
In summary, we have demonstrated that ductal morpho-
genesis in the pubertal mammary gland, both in vivo and in
culture, depends not only on the influence of morphoge-
netic factors but also on cell–ECM interactions transduced
by integrins. We propose that the extracellular matrix and
laminin in particular together with b1 integrins are crucial
o maintaining end bud structure and function and there-
ore that normal ductal development and mammary gland
orphogenesis require functional b1 integrins.
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